Neurocrine Biosciences | NBIX - Pre Tax Profit


Neurocrine Biosciences reported $246.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Exelixis USD 267.69M 15M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Prothena USD 32.72M 54.3M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Repligen USD 14.15M 12.38M Jun/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Teva Pharmaceutical Industries USD -455M 1.21B Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026